What Sets Us Apart

Scientific and Business Leadership

Credited with significant breakthroughs in the field, our distinguished team includes internationally renowned experts in the fields of stem cell biology, biotechnology, regenerative medicine and cGMP manufacturing, working alongside our accomplished business leaders to realize the great promise of stem cell technology.

Learn more about our People…

Learn more about our Science…

Learn more about our Clinical Programs…

Pioneering Clinical Translation for CNS Disorders

Our CNS Program is the most advanced neural stem cell clinical development program in the field. We have in process, or have completed, clinical programs that address disorders in all three regions of the CNS: the brain, the spinal cord and the eye. As the first ever to conduct a US clinical trial with human neural stem cells with a well-established safety profile, we are poised to be among the first to market a stem cell-based therapeutic product for CNS disorders.

Learn more about our Clinical Programs…

Homologous Approach Using Tissue-Derived “Adult” Stem Cells

We are focused on the use of tissue-derived “adult” stem cells for use in homologous therapy (i.e., the use of CNS-derived neural stem cells for the treatment of CNS disorders). Unlike embryonic or induced pluripotent stem (iPS) cells, tissue-derived stem cells need not be modified in any way before transplantation.

Learn more about our Approach…

Strong Intellectual Property Position

Our comprehensive IP portfolio is among the broadest and deepest in the field. With approximately 45 issued U.S. patents and 250 issued foreign patents, StemCells, Inc. is the undisputed leader in human neural stem cell research and development.

Learn more about our Intellectual Property…

Our cGMP manufacturing facility has been delivering HuCNS-SC® human neural stem cells for use in clinical trials since 2006.

StemCells, Inc. has been first to:

  • Discover, purify and expand a population of human neural stem cells and demonstrate that ex vivo expanded human neural stem cells engraft and show properties of true stem cells in vivo (PNAS, 2000)
  • Demonstrate the potential of human neural stem cells to treat numerous CNS disorders in animal models
  • Treat a human patient in an FDA authorized clinical trial using ex vivo expanded human neural stem cells (2006)
  • Demonstrate donor cell engraftment and migration following transplantation in a human patient
  • Conduct neural stem cell transplantation into the brain, spinal cord and eye (the only U.S. company ever to do so)
  • Demonstrate MRI evidence of de novo myelin in a human patient suffering from a myelination disorder (Pelizaeus-Merzbacher disease, a.k.a. PMD) using human neural stem cells
  • Have ongoing, FDA-authorized clinical trials utilizing human neural stem cells in spinal cord injury (SCI) and geographic atrophy of age-related macular degeneration (GA-AMD)
  • Demonstrate clinical evidence of efficacy for stem cells in chronic thoracic SCI and GA-AMD.